MADISON, N.J., Nov. 8 /PRNewswire-FirstCall/ -- Wyeth today announced the pricing of its offering of $1,500.0 million aggregate principal amount of senior notes, consisting of $1,000.0 million of 5.50% notes due February 15, 2016 and $500.0 million of 6.00% notes due February 15, 2036, to be issued inside the United States to qualified institutional buyers pursuant to Rule 144A under the U.S. Securities Act of 1933 (the “Securities Act”) and outside the United States pursuant to Regulation S under the Securities Act. The Company will use the proceeds from the senior notes for general corporate and working capital purposes.
The sale of the notes is expected to close on November 14, 2005, subject to standard closing conditions. Pursuant to an exchange and registration rights agreement, the Company will agree following the closing to offer to exchange the senior notes for identical notes registered under the Securities Act.
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities. The offering is being made only to qualified institutional buyers pursuant to Rule 144A and in transactions outside the United States pursuant to Regulation S. The notes being offered have not been registered under the United States federal or state securities laws and may not be offered or sold absent registration or an applicable exemption from the registration requirements.
Wyeth is one of the world’s largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products and nonprescription medicines that improve the quality of life for people worldwide. The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of the timing and success of pharmaceutical research, product development, manufacturing, commercialization, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, wars or terrorist acts, product liability and other types of lawsuits, the impact of legislation and regulatory compliance and obtaining reimbursement, favorable drug pricing, access and other approvals, environmental liabilities, and patent, and other risks and uncertainties, including those detailed from time to time in the Company’s periodic reports, including current reports on Form 8-K, quarterly reports on Form 10-Q and the annual report on Form 10-K, filed with the Securities and Exchange Commission. Actual results may vary materially from the forward-looking statements. The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Wyeth
CONTACT: Media: Douglas Petkus, +1-973-660-5218, or Investor: JustinVictoria, +1-973-660-5340, both of Wyeth
Web site: http://www.wyeth.com/
